Combined Dehydropeiandrosterone and Growth Hormone in Women With Expected Poor Ovarian Response Undergoing ICSI
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Two hundred and thirty women with expected poor ovarian response undergoing IVF/ICSI will be
randomly divided into 2 equal groups using computer generated random numbers. Group 1 will
receive DHEA 25 mg (DHEA 25mg, Natrol , USA) t.d.s for 12 weeks before starting IVF/ICSI
cycle in addition to Growth hormone (GH; Somatotropin, Sedico, Egypt) 4 IU on day 6 of human
menopausal gonadotropin (hMG) stimulation in a daily dose of 2.5 mg subcutaneous (sc) until
the day of human chorionic gonadotropin (hCG) triggering Group 2 will receive an oral placebo
t.d.s. daily for 12 weeks before ICSI in addition to a sc placebo similar to GH daily from
day 6 of stimulation until the day of hCG trigger.